Dr. Meyer-Bothling explains Diabetic Retinopathy treatment options – including Noctura 400
During Diabetes Week 2022 on TopDoctorsUK, the Chief Investigator of a recent successful Noctura 400...
PolyPhotonix Limited and embecta UK have announced they have signed a co-promotional agreement under which embecta sales representatives will promote PolyPhotonix’s Noctura 400 Sleep Mask to healthcare professionals within the UK and Ireland.
Summary:
PolyPhotonix Limited and embecta UK have entered a co-promotional agreement to promote PolyPhotonix’s Noctura 400 Sleep Mask to healthcare professionals in the UK and Ireland. The Noctura 400 Sleep Mask is a non-invasive, home-based monitored treatment for diabetic retinopathy, which can lead to blindness. The partnership will allow the companies to bring this innovative treatment to more patients faster, potentially reducing the rate of disease progression and associated loss of visual acuity. This treatment represents a cost-effective alternative to existing treatments and will free up hospital appointments for those in greater need of hospital-based care. Sinéad North, Country General Manager for embecta UK, highlighted that this agreement enables them to expand their offerings of diabetes care solutions to the NHS within an innovative new category.
Richard Kirk, CEO of PolyPhotonix, said: “Working with such an experienced team means that we can bring this innovative treatment to many more patients faster, potentially reducing the rate of disease progression and associated loss of visual acuity.”
